Results 11 to 20 of about 5,671 (151)

Role of abiraterone acetate in the management of metastatic prostate cancer [PDF]

open access: yesBatna Journal of Medical Sciences, 2023
Objective. to analyze the clinical, biological and histological profile of patients with prostate cancer and to assess the efficacy and safety of abiraterone acetate. Patients and methods.
Wafa Bechairia
doaj   +1 more source

Prescription pattern of abiraterone in Brazil - a survey of medical oncologists

open access: yesBrazilian Journal of Oncology, 2023
Introduction: Abiraterone acetate is widely used for the treatment of prostate cancer. In Brazil, the label dose is not affordable to most patients due to its elevated cost.
João Pedro Homse-Netto   +4 more
doaj   +1 more source

Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database [PDF]

open access: yesCancer Med
This real‐world study of the Flatiron Health database found that first‐line treatment with abiraterone versus enzalutamide was associated with significantly shorter overall survival, treatment duration, and time to subsequent treatment in patients with chemotherapy‐ and androgen receptor pathway inhibitor‐naïve metastatic castration‐resistant prostate ...
George D   +8 more
europepmc   +2 more sources

Abiraterone Acetate [PDF]

open access: yesDrugs in R&D, 2010
Abiraterone acetate (CB 7630; CB7630; JNJ-212082), the 3β-acetate prodrug of abiraterone, is structurally related to ketoconazole and is being developed by Cougar Biotechnology as a hormonal therapy for advanced prostate and breast cancers. As a selective inhibitor of adrenal androgens, it is thought to be a safer product than existing second-line ...
openaire   +3 more sources

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer

open access: yesIJU Case Reports, 2023
Introduction Transient decrease in serum prostate‐specific antigen level can occur after abiraterone acetate withdrawal in male patient with metastatic castration‐resistant prostate cancer.
Masaru Tani   +7 more
doaj   +1 more source

Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer

open access: yesScientific Reports, 2021
The objective of this study was to compare the efficacy of abiraterone acetate with that of bicalutamide in combination with gonadotropin-releasing hormone (GnRH) antagonist treatment for patients with high-risk metastatic hormone-sensitive prostate ...
Takashi Ueda   +9 more
doaj   +1 more source

Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

open access: yesFrontiers in Oncology, 2021
ObjectiveThe androgen receptor-targeting drugs abiraterone acetate and enzalutamide have shown positive results as treatments for metastatic castration-resistant prostate cancer (mCRPC).
ZhenHeng Wei   +4 more
doaj   +1 more source

Progress in A Real-world Study of Abiraterone Acetate Versus Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer

open access: yesZhongliu Fangzhi Yanjiu, 2023
The safety and survival benefits of abiraterone acetate and docetaxel in the treatment of patients with metastatic hormone-sensitive prostate cancer have been confirmed by randomized controlled trials and clinical studies abroad.
MA Dongsheng, AN Hengqing, WANG Yujie
doaj   +1 more source

Effect of Dexamethasone on Abiraterone Pharmacokinetics in Mice: Determined by LC/MS Analysis

open access: yesMedicines, 2023
Background: Abiraterone acetate is a cytochrome P450 17A1 (CYP17A1) inhibitor that is indicated for use in both castration-resistant and castration-sensitive prostate cancer patients.
Subrata Deb   +4 more
doaj   +1 more source

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer

open access: yesIJU Case Reports, 2019
Introduction Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration‐resistant prostate cancer. Case presentation A 62‐year‐old patient with a bone metastatic castration‐resistant prostate cancer was started ...
Yoshinori Yanai   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy